ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia.

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• B-cell chronic lymphocytic leukemia (B-CLL) is a heterogeneous lymphoid malignancy with unpredictable clinical outcomes.
• Identifying reliable prognostic markers is crucial for effective patient management and treatment stratification in B-CLL.

Purpose of the Study:

• To investigate the prognostic significance of ZAP-70 (zeta-chain-associated protein kinase 70) expression in B-cell chronic lymphocytic leukemia.
• To correlate ZAP-70 expression levels with clinical course, progression-free survival, and overall survival in B-CLL patients.

Main Methods:

• Semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) was used to detect ZAP-70 mRNA transcripts in purified leukemia B cells from 39 CLL patients.
• Flow-cytometric analysis was employed to confirm ZAP-70 protein expression in a larger cohort (n=67).
• Statistical analysis was performed on a combined cohort of 79 patients, comparing ZAP-70 positive and negative subgroups regarding survival and established prognostic factors (LDH, thymidine kinase, CD38).

Main Results:

• ZAP-70 mRNA was detected in 36% of B-CLL cases, with levels significantly higher than in control samples.
• ZAP-70 positive patients exhibited a significantly shorter progression-free survival (64%) compared to ZAP-70 negative patients.
• ZAP-70 expression status correlated with overall survival and other prognostic markers like LDH, thymidine kinase, and CD38 expression.

Conclusions:

• ZAP-70 expression serves as a robust prognostic marker in B-cell chronic lymphocytic leukemia.
• ZAP-70 positivity indicates an unfavorable clinical course and shorter survival, aiding in risk stratification.
• ZAP-70 levels remained stable over time in most patients, reinforcing its utility as a consistent prognostic indicator.